Clinical Trial

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Study acronym: PrevenTRON
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.
Trial Details
NCT Number NCT07717411
Lead Sponsor Hoffmann-La Roche
Conditions Alzheimer's Disease
Enrollment 1,600 participants
Start Date 2026-11-30
Primary Completion 2032-09-03 (estimated)
Study Completion 2032-09-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-21